NEUROPHET
AI-powered brain imaging analysis platform for neurological disorders
Software · Cloud SaaSCompany source
Company profile
About NEUROPHET
NEUROPHET is a medical imaging AI company specializing in quantitative brain analysis solutions for neurological conditions. The company develops FDA-cleared and CE-marked software that automates the analysis of brain MRI and PET imaging, providing clinicians with precise volumetric measurements, regional analysis, and longitudinal tracking capabilities. NEUROPHET's technology supports the diagnosis and monitoring of conditions including Alzheimer's disease, dementia, Parkinson's disease, epilepsy, and other neurological disorders. The platform integrates with existing radiology workflows and PACS systems to deliver standardized, reproducible brain imaging biomarkers. By combining deep learning algorithms with clinical neuroscience expertise, NEUROPHET aims to improve diagnostic accuracy, enable earlier detection of brain diseases, and support personalized treatment planning. The company serves hospitals, imaging centers, research institutions, and pharmaceutical companies conducting clinical trials. NEUROPHET's solutions are designed to address the growing need for objective, quantitative imaging analysis in an aging global population facing increasing rates of neurodegenerative diseases.
Company description NEUROPHET official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at NEUROPHET?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- dementia
- epilepsy
- neurodegenerative diseases
- neurological disorders
- Parkinson's disease
Who it serves
- hospitals
- imaging centers
- pharmaceutical companies
- research institutions
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Impact of adjunctive quantitative analysis on visual interpretation of amyloid PET: a multiple tracer, multicentre study.European radiology · Jun 18, 2026
Effects of apolipoprotein E ε4 on amyloid deposition and relative cerebral perfusion in cognitively normal individuals: a dual-phase 18F-florbetaben PET study.Nuclear medicine communications · Jun 2, 2026
Robust Quantification of Affected Brain Volume from Computed Tomography Perfusion: A Hybrid Approach Combining Deep Learning and Singular Value Decomposition.Journal of imaging informatics in medicine · Jun 1, 2026
A Landmark-Guided Dual-Stream Synergistic Framework for Automated Intracranial Aneurysm Detection in Magnetic Resonance Angiography.Journal of imaging informatics in medicine · May 18, 2026
Thalamo-cortical white matter connectivity-defined thalamic subarea volumes predict individual delay discounting.Molecular psychiatry · May 13, 2026
Impact of a structured quantitative program on [18F]FP-CIT PET interpretation: a multicenter study of diagnostic accuracy, interrater reliability, and reader confidence.The British journal of radiology · May 1, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Neurophet AQUA AD PlusK252496 · 510k · Jan 29, 2026
Neurophet AQUA (V3.1)K242215 · 510k · Oct 25, 2024
Neurophet AQUAK220437 · 510k · May 10, 2023
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from NEUROPHET
Recent articles published on NEUROPHET's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.